Society for Immunotherapy of Cancer 2021 NEWS
Meet and greet: SITC 2021
January 7, 2022 -- The Society for Immunotherapy of Cancer (SITC) 2021 meeting was an impactful event featuring the latest scientific and medical innovations in the field of immuno-oncology. These advances would not be possible if it were not for the dedicated professionals who work tirelessly to advance science's understanding of human health.
January 7, 2022 -- The Society for Immunotherapy of Cancer (SITC) 2021 meeting was an impactful event featuring the latest scientific and medical innovations in the field of immuno-oncology. These advances would not be possible if it were not for the dedicated professionals who work tirelessly to advance science's understanding of human health.
Battle royale: Self-cloaking virus vs. regenerating bacteria
January 7, 2022 -- Which one is more likely to win in a fight: a self-cloaking virus or regenerating bacteria? These two groups of microbes can wreak havoc on the human body, albeit in vastly different ways. While there may be no right or wrong answer, ScienceBoard has initiated a long-term effort to probe experts on where they would place their bets in this epic fight.
January 7, 2022 -- Which one is more likely to win in a fight: a self-cloaking virus or regenerating bacteria? These two groups of microbes can wreak havoc on the human body, albeit in vastly different ways. While there may be no right or wrong answer, ScienceBoard has initiated a long-term effort to probe experts on where they would place their bets in this epic fight.
Myxoma virus enters as an exciting preclinical cancer immunotherapy platform
November 18, 2021 -- A preclinical oncolytic viral vector platform under development was of interest at the recent Society for Immunotherapy of Cancer's 2021 annual meeting. OncoMyx Therapeutics' Chief Scientific Officer Leslie Sharp, PhD, spoke with ScienceBoard at the meeting.
November 18, 2021 -- A preclinical oncolytic viral vector platform under development was of interest at the recent Society for Immunotherapy of Cancer's 2021 annual meeting. OncoMyx Therapeutics' Chief Scientific Officer Leslie Sharp, PhD, spoke with ScienceBoard at the meeting.
5 takeaways from SITC 2021
November 17, 2021 -- WASHINGTON, DC - The Society for Immunotherapy of Cancer's (SITC) 2021 annual meeting November 10-14 was a successful gathering of research and clinical experts focused on the development of innovative cancer treatments. The ScienceBoard team was live onsite at the event. Editor in Chief Samantha Black, PhD, shared five takeaways from the meeting.
November 17, 2021 -- WASHINGTON, DC - The Society for Immunotherapy of Cancer's (SITC) 2021 annual meeting November 10-14 was a successful gathering of research and clinical experts focused on the development of innovative cancer treatments. The ScienceBoard team was live onsite at the event. Editor in Chief Samantha Black, PhD, shared five takeaways from the meeting.
Innovation and safety remain key amid shifting pandemic-impacted clinical trial protocols
November 16, 2021 -- WASHINGTON, DC - During the pandemic, clinical trial execution for cancer therapies has been challenging, said Dr. Samit Hirawat, chief medical officer at Bristol Myers Squibb, at the Society for Immunotherapy of Cancer's 2021 annual meeting. Despite the challenges presented by the pandemic, Hirawat noted that stakeholders held patient safety and innovation as key priorities. Hirawat spoke with ScienceBoard onsite at the meeting.
November 16, 2021 -- WASHINGTON, DC - During the pandemic, clinical trial execution for cancer therapies has been challenging, said Dr. Samit Hirawat, chief medical officer at Bristol Myers Squibb, at the Society for Immunotherapy of Cancer's 2021 annual meeting. Despite the challenges presented by the pandemic, Hirawat noted that stakeholders held patient safety and innovation as key priorities. Hirawat spoke with ScienceBoard onsite at the meeting.
Why one industry veteran launched a new cancer immunotherapy company
November 16, 2021 -- WASHINGTON, DC - Raphaël Ognar spoke with ScienceBoard onsite at the Society for Immunotherapy of Cancer's 2021 annual meeting about the launch of NKILT Therapeutics.
November 16, 2021 -- WASHINGTON, DC - Raphaël Ognar spoke with ScienceBoard onsite at the Society for Immunotherapy of Cancer's 2021 annual meeting about the launch of NKILT Therapeutics.
Where is the immunotherapy field headed after COVID-19?
November 15, 2021 -- WASHINGTON, DC - Best known for his contributions to the Moderna COVID-19 vaccine, former Moderna chief medical officer, Dr. Tal Zaks, PhD, chaired a session on RNA vaccines at the Society for Immunotherapy of Cancer's (SITC) 2021 annual meeting. Zaks shared his perspectives and hopeful outlook with ScienceBoard at the meeting.
November 15, 2021 -- WASHINGTON, DC - Best known for his contributions to the Moderna COVID-19 vaccine, former Moderna chief medical officer, Dr. Tal Zaks, PhD, chaired a session on RNA vaccines at the Society for Immunotherapy of Cancer's (SITC) 2021 annual meeting. Zaks shared his perspectives and hopeful outlook with ScienceBoard at the meeting.
Is the accelerated approval process working for cancer immunotherapies?
November 15, 2021 -- WASHINGTON, DC - Leveraging years of experience, Dr. Alessandra Cesano, PhD, who serves on the board of directors of the Society for Immunotherapy of Cancer (SITC), chaired a panel discussion on the accelerated approval process for cancer immunotherapies at the organization’s 2021 annual meeting. Cesano spoke with ScienceBoard at the meeting.
November 15, 2021 -- WASHINGTON, DC - Leveraging years of experience, Dr. Alessandra Cesano, PhD, who serves on the board of directors of the Society for Immunotherapy of Cancer (SITC), chaired a panel discussion on the accelerated approval process for cancer immunotherapies at the organization’s 2021 annual meeting. Cesano spoke with ScienceBoard at the meeting.
Researchers dig into how myeloid cells contribute to killing cancer
November 15, 2021 -- WASHINGTON, DC - Dr. Miriam Merad, PhD, director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai is working on characterizing myeloid cells in cancer patients. Merad spoke with ScienceBoard at the Society for Immunotherapy of Cancer's 2021 annual meeting.
November 15, 2021 -- WASHINGTON, DC - Dr. Miriam Merad, PhD, director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai is working on characterizing myeloid cells in cancer patients. Merad spoke with ScienceBoard at the Society for Immunotherapy of Cancer's 2021 annual meeting.
New neoadjuvant platform helps inform combo immunotherapy selection for cancers
November 13, 2021 -- WASHINGTON, DC - In order to address some of the major challenges facing the immuno-oncology field, Dr. Tom Marron, PhD, has developed a platform to help researchers decide which drugs or combination of drugs to advance toward late-stage clinical trials. Marron spoke with ScienceBoard Editor in Chief, Samantha Black, PhD, onsite at the Society for Immunotherapy of Cancer's 2021 annual meeting.
November 13, 2021 -- WASHINGTON, DC - In order to address some of the major challenges facing the immuno-oncology field, Dr. Tom Marron, PhD, has developed a platform to help researchers decide which drugs or combination of drugs to advance toward late-stage clinical trials. Marron spoke with ScienceBoard Editor in Chief, Samantha Black, PhD, onsite at the Society for Immunotherapy of Cancer's 2021 annual meeting.
Society for Immunotherapy of Cancer 2021 Industry News
Applied Biomath highlights presentations at SITC meeting
November 4, 2021 -- Applied Biomath is highlighting two poster presentations being offered at the upcoming Society for Immunotherapy of Cancer (SITC) meeting in Washington, DC. Read More
ImmunoGenesis data to be presented at SITC 2021
November 3, 2021 -- Data from ImmunoGenesis will be presented at the Society for Immunotherapy of Cancer (SITC) annual meeting scheduled for November 10-14 in Washington, DC. Read More
Incyte to showcase oncology portfolio at SITC
November 1, 2021 -- Incyte plans to highlight clinical study data for its oncology portfolio at the upcoming Society for Immunotherapy of Cancer (SITC) 2021 annual meeting in Washington, DC, November 12-13, 2021. Read More
Immatics to highlight ACTengine program updates at SITC
November 1, 2021 -- Immatics plans to offer an update on its ACTengine IMA203 trial at the upcoming Society for Immunotherapy of Cancer (SITC) 2021 annual meeting in Washington, DC, November 12-13. Read More
BioNTech to highlight clinical results from CAR T program
November 1, 2021 -- BioNTech plans to highlight new clinical data from a phase I/II trial of its BNT211 CAR T-cell therapy candidate at the Society for Immunotherapy of Cancer meeting in Washington, DC, on November 12. Read More